Summary
- GARS1 expression levels were higher in various cancers compared to normal tissues, including BLCA, COAD, LIHC, and UCEC, among others.
- Acute myeloid leukemia showed lower GARS1 expression compared to normal tissue.
- GARS1 expression correlated with overall survival in several cancers, with high expression being a high-risk indicator in ACC and KICH.
- GARS1 had diagnostic value in identifying tumors from normal cells in various cancers with high accuracy, based on ROC curve analysis.
- GARS1 was associated with immune cells and gene markers in BLCA, promoting cell proliferation, metastasis, and inhibiting apoptosis in vitro.
A study recently looked into the role of a gene called GARS1 in various types of cancer, including bladder, colon, liver, and stomach cancer. The researchers observed that high levels of GARS1 were associated with poorer overall survival in several cancers, including bladder and breast cancer. On the other hand, high GARS1 levels were linked to better survival in certain types of cancer, such as thymoma. Additionally, the study found that GARS1 was highly expressed in many cancer cell lines, indicating its involvement in cancer development.
The researchers also explored the relationship between GARS1 expression and immune cells in cancer. They discovered that GARS1 expression was positively correlated with certain immune cells in most cancer types, suggesting that GARS1 may play a role in regulating the immune response in cancer. Furthermore, the study investigated the genetic alterations and DNA methylation status of GARS1 in bladder cancer, revealing low levels of DNA methylation in high-grade tumors.
In laboratory experiments, the researchers manipulated GARS1 expression in bladder cancer cells to study its effects on cell proliferation, metastasis, and apoptosis. They found that overexpression of GARS1 promoted cell growth and invasiveness, while depletion of GARS1 hindered these processes. Moreover, altering GARS1 expression impacted the apoptosis rate of cancer cells, with higher GARS1 levels inhibiting cell death.
Overall, this study sheds light on the role of GARS1 in cancer development and progression, highlighting its potential as a therapeutic target for certain cancer types.
Source link
Oncology, Urology
